New hope for hodgkin lymphoma: drug combo aims to boost transplant success
NCT ID NCT05180097
First seen Feb 02, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This phase 2 trial tests whether combining two drugs, pembrolizumab and brentuximab vedotin, can better shrink or eliminate Hodgkin lymphoma compared to standard chemotherapy (GDP) before a stem cell transplant. About 84 adults with relapsed or refractory classical Hodgkin lymphoma will participate. The goal is to see if the new combo leads to higher complete response rates and better long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Allan Blair Cancer Centre
RECRUITINGRegina, Saskatchewan, S4T 7T1, Canada
Contact Phone: •••-•••-••••
-
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITINGCalgary, Alberta, T2N 5G2, Canada
Contact Phone: •••-•••-••••
-
Austin Hospital
RECRUITINGHeidelberg, Victoria, 3084, Australia
Contact Phone: •••-•••-••••
-
BCCA - Vancouver
RECRUITINGVancouver, British Columbia, V5Z 4E6, Canada
Contact Phone: •••-•••-••••
-
CIUSSS de l'Estrie - Centre hospitalier
RECRUITINGSherbrooke, Quebec, J1H 5N4, Canada
Contact Phone: •••-•••-••••
-
Concord Repatriation General Hospital
RECRUITINGConcord, New South Wales, 2139, Australia
Contact
-
Dr. H. Bliss Murphy Cancer Centre
RECRUITINGSt. John's, Newfoundland and Labrador, A1B 3V6, Canada
Contact Phone: •••-•••-••••
-
Juravinski Cancer Centre at Hamilton Health Sciences
RECRUITINGHamilton, Ontario, L8V 5C2, Canada
Contact Phone: •••-•••-••••
-
London Health Sciences Centre Research Inc.
RECRUITINGLondon, Ontario, N6A 5W9, Canada
Contact Phone: •••-•••-••••
-
Ottawa Hospital Research Institute
RECRUITINGOttawa, Ontario, K1H 8L6, Canada
Contact Phone: •••-•••-••••
-
QEII Health Sciences Centre
RECRUITINGHalifax, Nova Scotia, B3H 1V7, Canada
Contact Phone: •••-•••-••••
-
Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-••••
-
Shoalhaven Cancer Care Centre
RECRUITINGNowra, New South Wales, 2541, Australia
Contact
-
Sir Charles Gairdner Hospital
RECRUITINGPerth, Western Australia, 6009, Australia
Contact
-
The Jewish General Hospital
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
Contact Phone: •••-•••-••••
-
The Research Institute of the McGill University
RECRUITINGMontreal, Quebec, H4A 3J1, Canada
Contact Phone: •••-•••-••••
-
University Health Network
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
-
Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab and brentuximab vedotin
What this could lead to
If successful, this combination could offer a more effective way to shrink or eliminate Hodgkin lymphoma before a stem cell transplant, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase trial with only 84 participants, so results may not apply to everyone. The drugs can cause serious side effects, and it's unknown if they will work better than standard treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.